A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind.

ABSTRACT: Chemotherapy remains a commonly used and important treatment option for metastatic breast cancer. A majority of ER+ metastatic breast cancer patients ultimately develop resistance to chemotherapy, resulting in disease progression. We hypothesized that an "evolutionary double-bind", where treatment with one drug improves the response to a different agent, would improve the effectiveness and durability of responses to chemotherapy. This approach exploits vulnerabilities in acquired resistance mechanisms. Evolutionary models can be used in refractory cancer to identify alternative treatment strategies that capitalize on acquired vulnerabilities and resistance traits for improved outcomes. To develop and test these models, ER+ breast cancer cell lineages sensitive and resistant to chemotherapy

SUBMITTER: Emond R 

PROVIDER: S-EPMC11398327 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature